Currently out of the existing stock ratings of Matthew Keller, 21 are a BUY (100%).

Matthew Keller

Work Performance Price Targets & Ratings Chart

Analyst Matthew Keller, has had 26.19% of price targets met with an average potential upside of 91.53%, reached in 78 days on average.

Matthew Keller has documented 39 price targets and ratings displayed on 7 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ACXP, Acurx Pharmaceuticals LLC.

Wall Street Analyst Matthew Keller

Analyst best performing recommendations are on IFRX (INFLARX N.V.).
The best stock recommendation documented was for IFRX (INFLARX N.V.) on 12/30/2025. The price target of $6 was fulfilled within 269 days with a profit of $4.98 (488.24%), with a performance score of 18.15.

Average potential price target upside

GRI GRI Bio SNSE Sensei Biotherapeutics GALT Galectin Therapeutics IFRX InflaRx N.V. PHIO Phio Pharmaceuticals Corp ACXP Acurx Pharmaceuticals LLC FGEN FibroGen

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 02-Jul-2025

$10

$8.3 (488.24%)

$280.11

2 months 6 days ago
(10-Sep-2026)

0/2 (0%)

$8.06 (415.46%)

Buy Since 05-Dec-2024

$36

8 months 5 days ago
(11-Mar-2026)

5/5 (100%)

$-1.8 (-4.76%)

53

Buy Since 09-Dec-2024

$10.08

$10.08

1 years 5 months 5 days ago
(11-Jun-2025)

3/3 (100%)

$-26.88 (-72.73%)

178

Show more analysts

Please expand the browser size to see the chart

Which stock is Matthew Keller most bullish on?

Potential upside of $9.97 has been obtained for ACXP (ACURX PHARMACEUTICALS LLC)

Which stock is Matthew Keller most reserved on?

Potential downside of -$0 has been obtained for PHIO (PHIO PHARMACEUTICALS CORP)
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?